# Symbiomix Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/symbiomix-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Newark, US
- Website: www.symbiomix.com
- Total disclosed funding: $41M
- Latest round: Series A (May 5, 2015)
- Investors on record: 4

## About

Symbiomix Therapeutics, LLC is a biopharmaceutical company focused on developing innovative treatments for women's health, particularly in the area of infectious diseases and microbiome-related conditions.Founded in 2012 and headquartered in Newark, US, Symbiomix Therapeutics focuses on developing therapies for women's health. The company was acquired in October 2017 by Lupin Limited for USD 150 mn, which included an upfront payment of USD 50 mn and additional time-based payments. The acquisition followed a series of three deals involving the company's operations.Symbiomix Therapeutics specializes in delivering innovative biopharmaceutical solutions aimed at improving women's health. Their flagship products target infectious diseases and microbiome-related conditions, developed with extensive research and testing. The products are marketed globally, ensuring they meet the specific needs of healthcare providers and patients across diverse regions, including North America, Europe, and Asia.Symbiomix Therapeutics operates a revenue model primarily based on product sales, which are driven by the demand for effective treatments in women's health. Their primary product offerings are situated at various price points, enabling access for a broad spectrum of healthcare facilities, from small clinics to larger hospitals. This structured approach fosters long-term relationships with healthcare providers and contributes to a steady income stream.Looking ahead, Symbiomix Therapeutics plans to expand its product offerings with new treatments aimed at addressing unmet needs in women's health, although specific release dates are not disclosed. Furthermore, the company targets expansion into additional markets across Europe and Asia, aiming to establish a stronger presence by 2025. The recent acquisition by Lupin Limited will support these growth initiatives, leveraging additional resources for research and development to enhance their product pipeline.

## Funding rounds

- Series A, May 5, 2015, $41M — OrbiMed Advisors, HBM Partners, F-Prime Capital, Square 1 Bank

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series A
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A
- Square 1 Bank — Series A